Expression of PTK7 among cytogenetic and molecular AML clusters
| AML subgroup . | n . | PTK7+, no. (%) . |
|---|---|---|
| APL | 18 | 18 (100) |
| CBF | 21 | 19 (90) |
| NPM mutated | 9 | 2 (22) |
| Trisomy 8 | 15 | 11 (73) |
| Normal karyotype | 65 | 56 (86) |
| Standard-risk karyotype | 29 | 20 (69) |
| FLT3+ | 27 | 14 (51) |
| MLL | 13 | 5 (38) |
| Del 5q or-7 | 24 | 21 (88) |
| 3q implication Inv(3) | 5 | 1 (20) |
| Complex karyotype | 30 | 53 (67) |
| AML subgroup . | n . | PTK7+, no. (%) . |
|---|---|---|
| APL | 18 | 18 (100) |
| CBF | 21 | 19 (90) |
| NPM mutated | 9 | 2 (22) |
| Trisomy 8 | 15 | 11 (73) |
| Normal karyotype | 65 | 56 (86) |
| Standard-risk karyotype | 29 | 20 (69) |
| FLT3+ | 27 | 14 (51) |
| MLL | 13 | 5 (38) |
| Del 5q or-7 | 24 | 21 (88) |
| 3q implication Inv(3) | 5 | 1 (20) |
| Complex karyotype | 30 | 53 (67) |
CBF indicates core binding factor; NPM mutated, AML with normal karyotype and FLT3-ITD; FLT3+, AML with normal karyotype and FLT3-ITD or FLT3 exon 20 mutation; MLL, mixed lineage leukemia (includes all 11q23 abnormalities); and Inv(3), inversion of chromosome 3 (correlates with the implication of Evi-1 gene).